Premium
Review of long‐term treatment with labetalol.
Author(s) -
WaalManning HJ,
Simpson FO
Publication year - 1982
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/j.1365-2125.1982.tb01891.x
Subject(s) - labetalol , medicine , blood pressure , diuretic , blockade , anesthesia , pharmacology , receptor
1 Labetalol has been used to treat 163 patients at the Dunedin Hypertension Clinic for periods up to 6.5 y, and of 128 patients in a New Zealand multicentre study for 2 yr. 2 Labetalol was often effective when other anti‐hypertensive agents, including beta‐blockers, had failed. It was usually given with a diuretic. 3 Mean daily dose was 700 mg (range 100‐2400 mg). No tolerance to the anti‐hypertensive effect was seen. 4 Some postural‐induced decrease in blood pressure on labetalol was common. 5 Side‐effects led to withdrawal of labetalol in about 25% of patients, mainly during the first few months of therapy. Another 25% had minor side‐effects but could continue with the drug. 6 There were three types of side‐effects (in order of frequency): (a) non‐ specific, (b) related to alpha‐blockade and (c) related to beta‐ blockade. The latter were much less troublesome than on “pure” beta‐ blockers. 7 There was no significant evidence of renal haematological or hepatic toxicity. 8 Anti‐nuclear antibody tests became positive on labetalol in about 15%, usually at low titres but in one patient the titre increased to a high level and fell when labetalol was stopped. 9 In a subset of 25 patients who took labetalol for the longest time (up to 6.5 yr) there was a 16% incidence of anti‐mitochondrial antibodies.